Veröffentlichungen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Bunse, Mario Dr. (3) Chen, Wei Prof. Dr. (1) Edes, Inan Dr. (1) Gavvovidis, Ioannis Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (2) Kettenmann, Helmut Prof. Dr. (2) Kieback, Elisa Dr. (2) Ku, Min-Chi Dr. (1) Leisegang, Matthias Dr. (6) Lorenz, Felix Dr. (4) Niendorf, Thoralf Prof. Dr. (1) Poncette, Lucia (1) Singh, Manvendra Dr. (1) Uckert, Wolfgang Prof. Dr. (20) Waiczies, Helmar Dr. (1) Waiczies, Sonia Dr. (1) Wolf, Susanne Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (6) Bioinformatics (1) Biologie maligner Lymphome (14) Experimentelle Genetik von Herz- Kreislauferkrankungen (2) Immunregulation und Krebs (1) Molekulare Immunologie und Gentherapie (18) Molekulare Immuntherapie (3) (-) Molekulare Zellbiologie und Gentherapie (6) Proteom Dynamik (1) Signaltransduktion in Tumorzellen (2) Strukturbiologie Membran-assoziierter Prozesse (1) Systembiologie von Gen-regulatorischen Elementen (1) 1998 (2) 2000 (2) 2003 (4) 2004 (1) 2005 (3) 2006 (2) 2007 (1) 2008 (1) 2010 (1) (-) 2011 (2) 2014 (1) (-) 2015 (2) (-) 2016 (1) 2017 (1) (-) 2019 (1) 6 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Molekulare Zellbiologie und Gentherapie2011201520162019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 02. Januar 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein 01. März 2016 in J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein 01. April 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber 01. April 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein 28. Juli 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 15. Januar 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
02. Januar 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
01. März 2016 in J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein
01. April 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
01. April 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
28. Juli 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
15. Januar 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
